Future Directions of Marine Myxobacteria and Their Natural Products
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 209
Special Issue Editor
Interests: microorganisms; myxobacteria; microbial natural products; drug discovery; phylogeny; taxonomy; systematics; metagenomics; genomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last two decades, the myxobacteria that tolerate sea salts have emerged as distinct groups in the order Myxococcales. Similar to their terrestrial counterpart, the halophilic myxobacteria synthesize diverse and exclusive secondary metabolites with interesting antimicrobial and cytotoxic biological activities. Most of the compounds isolated and structurally elucidated are from the genera Enhygromyxa and Haliangium; however, very little is known about secondary metabolites from the few other marine- and estuarine- derived taxa. Since metagenomic studies indicate that marine myxobacteria are more diverse than expected in salt-containing habitats and host organisms such as sponges and seagrasses, the discovery of new compounds in the future can be expected. Moreover, some studies have linked the possible myxobacterial associations with marine sponges to the parallel production of similar compounds as in the cases of apicularen A and salicylihalamide A, bengamide E-F, chondromide A-D and jasplakinolide, microsclerodermin D, and saframycin Mx1 and renieramycin A. Although the cultivation of these microorganisms is very challenging due to their slow growth rate and poorly understood physiology, marine myxobacteria may still be worth investigating to discover novel compounds.
This Special Issue aims to invite scientists, researchers and academics to publish their latest findings within the following scope for marine- and estuarine-derived myxobacteria: 1) isolation and discovery of novel taxa; 2) metagenomic diversity, phylogenetic and genomic studies; 3) biosynthesis and metabolomics; 4) isolation and structure elucidation of novel compounds; 5) mode-of-action and structure-activity-related (SAR) studies of novel compounds.
Dr. Ronald O. Garcia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Myxobacteria
- Halophilic
- Secondary metabolites
- Bioactive compounds
- Structure-activity-related (SAR) studies
- Drugs from marine myxobacteria
- Metagenomics
- Biodiversity
- Phylogenetics
- Biosynthesis
- Metabolomics
- Genomics
